Status:
RECRUITING
Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
Lead Sponsor:
University Hospital, Limoges
Conditions:
Glioma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sen...
Detailed Description
Gliomas are the most common primary brain tumors in adults. The heterogeneity of tumors, the lack of reliable criteria for identifying different subtypes make their histopathological diagnosis and the...
Eligibility Criteria
Inclusion
- Subject of both sexes at least 18 years of age with glioblastoma.
- Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol)
- Patient affiliated to French social security
Exclusion
- Patient included in another research protocol using an experimental molecule.
- Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol
- Patient under legal protection, guardianship or curatorship
- Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.
Key Trial Info
Start Date :
April 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06116903
Start Date
April 11 2024
End Date
December 15 2025
Last Update
December 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Limoges
Limoges, France, 87042